CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
6.92
-0.37 (-5.08%)
At close: Nov 7, 2025, 4:00 PM EST
6.99
+0.07 (1.01%)
After-hours: Nov 7, 2025, 7:57 PM EST
CervoMed Employees
CervoMed had 15 employees as of December 31, 2024. The number of employees increased by 7 or 87.50% compared to the previous year.
Employees
15
Change (1Y)
7
Growth (1Y)
87.50%
Revenue / Employee
$518,465
Profits / Employee
-$1,507,460
Market Cap
64.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRVO News
- 18 days ago - CervoMed to Present at the Emerging Growth Conference - GlobeNewsWire
- 4 weeks ago - CervoMed Drug Cut Dementia Progression Risk By 75% In Trial - Benzinga
- 4 weeks ago - CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies - GlobeNewsWire
- 5 weeks ago - CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 7 weeks ago - CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference - GlobeNewsWire
- 2 months ago - CervoMed to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - CervoMed's Dementia Data Show Slowed Disease Progression - Benzinga
- 3 months ago - CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration - GlobeNewsWire